Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The standard treatment for patients with HL that has not responded to treatment or has come
back after treatment is stem cell transplant. When patients are not eligible for transplant
or when HL comes back after transplant, there are no standard treatment options. These
patients can receive chemotherapy or participate in clinical trials. Bendamustine HCl is a
chemotherapy agent that is effective in treating patients with various diseases, including
non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. It was recently approved for the
treatment of chronic lymphocytic leukemia. In addition, small studies from Eastern Europe
have shown that bendamustine HCl is likely effective for treating HL. This study will find
out the effect of bendamustine HCl for transplant-ineligible patients with HL that has not
responded to or has come back after treatment.